OneSource Specialty Pharma Ltd (ONESOURCE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 10039523, "name": "OneSource Speci.", "stock_name": "OneSource Speci.", "full_name": "OneSource Specialty Pharma Ltd", "name_url": "stocks-analysis/onesource-speci", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,534.00", "chg": -25.75, "chgp": "-1.65%", "dir": -1, "prev_price": "1,559.75", "mcapval": "17,770.00 Cr", "mcap": "Small Cap", "scripcode": 544292, "symbol": "ONESOURCE", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE013P01021", "curr_date": "Aug 04, 03:30 PM", "curr_time": "01:42 AM", "last_traded_at": "Aug 04, 03:30 PM IST", "bse_nse_vol": "2.79 lacs", "exc_status": "Active", "traded_date": "Aug 04, 2026", "traded_date_str": "2026 08 04", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/onesource-speci-10039523-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "OneSource Specialty Pharma Ltd Faces Technical Momentum Shift Amid Market Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/onesource-specialty-pharma-ltd-faces-technical-momentum-shift-amid-market-pressure-4135540", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/OneSourceSpecia_technicaldot_4135540.png", "date": "2026-08-04 08:11:27", "description": "OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish stance to a sideways trend. This change comes amid a sharp price decline and deteriorating market sentiment, raising concerns for investors in the Pharmaceuticals & Biotechnology sector." }, { "title": "OneSource Specialty Pharma Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/onesource-specialty-pharma-ltd-is-rated-hold-4133667", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/OneSourceSpecia_mojoScore_4133667.png", "date": "2026-08-03 10:10:04", "description": "OneSource Specialty Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "OneSource Specialty Pharma Ltd Technical Momentum Shifts Signal Mild Bullish Outlook", "link": "https://www.marketsmojo.com/news/stocks-in-action/onesource-specialty-pharma-ltd-technical-momentum-shifts-signal-mild-bullish-outlook-4121925", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OneSourceSpecia_technicaldot_4121925.png", "date": "2026-07-27 08:03:29", "description": "OneSource Specialty Pharma Ltd has recently shifted from a sideways technical trend to a mildly bullish stance, reflecting a nuanced change in price momentum. Despite a modest day change of -0.02%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse amid broader market conditions." }, { "title": "Are OneSource Specialty Pharma Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-onesource-specialty-pharma-ltd-latest-results-good-or-bad-4120832", "imagepath": "", "date": "2026-07-25 19:17:30", "description": "OneSource Specialty Pharma Ltd's latest financial results for Q1 FY27 reveal a complex operational landscape characterized by significant revenue growth but persistent profitability challenges. The company reported a net profit of ₹25.00 crores, marking a substantial improvement from the previous quarter, where it had recorded a loss. This turnaround reflects a 443.48% increase in net profit quarter-on-quarter, indicating a return to profitability after a challenging period.\n\nRevenue for the quarter reached ₹449.02 crores, representing a 37.20% year-on-year growth and a sequential increase of 4.86% from the previous quarter. This performance highlights the company's ability to generate robust top-line growth, driven by strong market traction for its specialty pharmaceutical products. However, the operating margin stood at 27.47%, which, despite being an improvement from the previous quarter's 21.47%, remain..." }, { "title": "OneSource Specialty Pharma Gains 0.18%: 3 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/onesource-specialty-pharma-gains-018-3-key-factors-driving-the-week-4120029", "imagepath": "", "date": "2026-07-25 10:00:06", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>20 Jul:</strong> Stock opens strong at Rs.1,694.95 (+2.70%) despite flat Sensex</p>\n <p><strong>22 Jul:</strong> Mojo Grade upgraded to Hold reflecting mixed financial and technical signals</p>\n <p><strong>23 Jul:</strong> Mildly bullish momentum observed with 1.54% price gain</p>\n <p><strong>24 Jul:</strong> Technical momentum shifts to sideways trend amid mixed market signals</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,650.45</div></div>\n <div class=\"stat-item\"><div class..." }, { "title": "OneSource Specialty Pharma Q1 FY27: Return to Profitability Masks Underlying Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/onesource-specialty-pharma-q1-fy27-return-to-profitability-masks-underlying-concerns-4120461", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OneSourceSpecia_quaterlyResult_4120461.png", "date": "2026-07-25 09:51:08", "description": "OneSource Specialty Pharma Ltd. posted a consolidated net profit of ₹25.00 crores in Q1 FY27, marking a dramatic turnaround from the ₹0.19 crore loss in Q1 FY26, though the stock has struggled to maintain momentum, declining 16.07% over the past year. The ₹18,862 crore market capitalisation pharmaceutical company delivered sequential growth of 443.48% in net profit compared to Q4 FY26's ₹4.60 crores, whilst revenue expanded 37.20% year-on-year to ₹449.02 crores." }, { "title": "OneSource Specialty Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/onesource-specialty-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-4118683", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OneSourceSpecia_technicaldot_4118683.png", "date": "2026-07-24 08:03:55", "description": "OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of indicator signals. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s price action and technical indicators suggest a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector." }, { "title": "OneSource Specialty Pharma Ltd Upgraded to Hold Amid Mixed Financial and Technical Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/onesource-specialty-pharma-ltd-upgraded-to-hold-amid-mixed-financial-and-technical-signals-4117269", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OneSourceSpecia_mojoScore_4117269.png", "date": "2026-07-23 08:34:30", "description": "OneSource Specialty Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and financial trends despite ongoing challenges in profitability and valuation. The upgrade, effective from 22 July 2026, is driven primarily by a shift in technical momentum and a stabilisation in long-term sales growth, signalling cautious optimism for investors in this small-cap pharmaceutical player." }, { "title": "OneSource Specialty Pharma Ltd Shows Mildly Bullish Momentum Amid Mixed Technical Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/onesource-specialty-pharma-ltd-shows-mildly-bullish-momentum-amid-mixed-technical-signals-4117153", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/OneSourceSpecia_technicaldot_4117153.png", "date": "2026-07-23 08:05:29", "description": "OneSource Specialty Pharma Ltd has shifted from a sideways technical trend to a mildly bullish stance, reflecting a nuanced change in price momentum. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent performance suggests cautious optimism for investors in the Pharmaceuticals & Biotechnology sector." } ], "total": 241, "sid": "10039523", "stock_news_url": "https://www.marketsmojo.com/news/onesource-specialty-pharma-10039523" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript", "datetime": "31-Jul-2026", "details": "Intimation of Transcript of Earnings call dated July 25 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Management", "datetime": "27-Jul-2026", "details": "Changes in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "26-Jul-2026", "details": "Intimation about publication of newspaper advertisement- Extract of unaudited Standalone and Consolidated financial results for the quarter ended June 30 2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

20 Jul: Stock opens strong at Rs.1,694.95 (+2.70%) despite flat Sensex

22 Jul: Mojo Grade upgraded to Hold reflecting mixed financial and technical signals

23 Jul: Mildly bullish momentum observed with 1.54% price gain

24 Jul: Technical momentum shifts to sideways trend amid mixed market signals

Week Open

Rs.1,650.45

Read full news article

OneSource Specialty Pharma Q1 FY27: Return to Profitability Masks Underlying Concerns

2026-07-25 09:51:08

OneSource Specialty Pharma Ltd. posted a consolidated net profit of ₹25.00 crores in Q1 FY27, marking a dramatic turnaround from the ₹0.19 crore loss in Q1 FY26, though the stock has struggled to maintain momentum, declining 16.07% over the past year. The ₹18,862 crore market capitalisation pharmaceutical company delivered sequential growth of 443.48% in net profit compared to Q4 FY26's ₹4.60 crores, whilst revenue expanded 37.20% year-on-year to ₹449.02 crores.

Read full news article

OneSource Specialty Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-07-24 08:03:55

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of indicator signals. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s price action and technical indicators suggest a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

OneSource Specialty Pharma Ltd Upgraded to Hold Amid Mixed Financial and Technical Signals

2026-07-23 08:34:30

OneSource Specialty Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and financial trends despite ongoing challenges in profitability and valuation. The upgrade, effective from 22 July 2026, is driven primarily by a shift in technical momentum and a stabilisation in long-term sales growth, signalling cautious optimism for investors in this small-cap pharmaceutical player.

Read full news article

OneSource Specialty Pharma Ltd Shows Mildly Bullish Momentum Amid Mixed Technical Signals

2026-07-23 08:05:29

OneSource Specialty Pharma Ltd has shifted from a sideways technical trend to a mildly bullish stance, reflecting a nuanced change in price momentum. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent performance suggests cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article